Cutaneous Lymphadenoma: A Case Report and Literature Review

Abstract

Cutaneous lymphadenoma (CL) is an uncommon epithelioid tumor that is usually present on the head and face. It was first described by Santa Cruz and Barr in 1987, as a lymphoepithelial tumor, and was renamed as CL in 1991. Although CL is considered as a benign tumor, there are cases of recurrence after shave excision and metastasis to regional lymph nodes. Correct diagnosis and complete resection are of great importance. Here, we report a typical case of CL and make a comprehensive review of this rare skin tumor.

Keywords:

• cutaneous lymphadenoma
• skin tumor
• carcinoma

Introduction

CL is an uncommon skin neoplasm with a predilection for the head and face, particularly the cheek, eyebrow, and forehead. Less than 100 cases have been reported in the literature since it was named in 1991,^1,2 of which, only 5 cases were reported by China. There is still controversy both on its histogenesis and diagnosis. A recent study showed that CL expressing hair follicle bulge stem cell CK15, PHLDA1 and androgen receptor (AR), considering that CL was a distinct benign lymphoepithelial tumor.³ Although it exhibits benign biologic behavior, it could resemble closely to other non-melanoma skin cancers both clinically and histologically, there are also cases of recurrence after shave excision and metastasis to regional lymph nodes, so recognition of CL is of great importance.^4,5 Here we report a case of CL in an 80-year-old woman. Written informed consent for publication of the details was obtained from the patient.

Case Presentation

An 80-year-old woman claimed a single small nodule existed on the left side of her nose for 10 years, slowly increasing in size, without any uncomfortable feelings. She was otherwise in good health except for hypertension, with no previous history of any other skin diseases. Physical examination showed a clearly circumscribed semicircular nodule on the left side of the alar of her nose, 9 mm in diameter, skin color, moderate hardness, with smooth surface and telangiectasis, without ulcer and crust (see Figure 1). The clinical impression was a kind of adnexal tumor, and the lesion was completely excised with a 5-mm surgical margin of clinically normal skin and submitted for further histopathology and immunohistochemical study. No recurrence or metastasis had been observed since postoperative follow-ups for 1 year (both by clinical visit and telephone).

Figure 1 A skin color, semicircular nodule on the left side of the alar of the nose, with telangiectasis on the surface.

Histologic examination showed normal epidermis (See Figure 2), there were several well-circumscribed irregular shaped nodules in the dermis, which were enmeshed in a dense fibrous stroma. At higher magnification, the epithelial nodules were rimmed by a palisading of one or two layers of dark stained basaloid cells, without contraction gap around. In the center of the nodule, there were many large transparent cells with clear cytoplasm, rich in glycogen and vesicular nuclei (named Reed–Sternberg-like cells: RS-L cells), scattered with some lymphocytes. There were prominent lymphoid cells infiltration around the nodules (see Figures 2 and 3). Immunohistochemical study showed cytokeratin and epithelial membrane antigen (EMA) were positive (see Figure 4), and carcinoma embryonic antigen (CEA) was negative. The infiltration was composed of a mixture of T and B lymphocytes, with a predominance of T cells (see Figures 5 and 6). CD30+ cells (RS-L cells) (see Figure 7) are scattered in the center of the lobules, which may be representing activated lymphocytes and histiocytes. S100-positive dendritic cells were stained, and co-expressed CD1a (see Figures 8 and 9), possibly represent Langerhans cells.

Figure 2 The tumor composed of irregularly shaped lobules enmeshed in a dense fibrous stroma.

Figure 3 The lobules had a peripheral rim of 1 or 2 layers of basaloid cells, central RS-L cells, and lymphocytes infiltration around. (Magnification ×10).

Figure 4 EMA-positive staining of the ductal structures. (Magnification ×200).

Figure 5 T cells were the predominantly infiltrated cells in CL, T cell receptor marker CD3. (Magnification ×200).

Figure 6 B cell marker CD20. (Magnification ×200).

Figure 7 RS-L cell marker CD30. (Magnification ×200).

Figure 8 CD1a positive staining of many intralobular dendritic cells. (Magnification ×200).

Figure 9 S-100-positive staining of many intralobular dendritic cells. (Magnification ×200).

Discussion and Literature Review of CL

According to the typical histopathological and immunohistochemical characteristics, it is not difficult to make the correct diagnosis of CL in this case. Up to now, less than 100 cases of CL have been reported worldwide, and there was no significant gender difference, with ages varying from newborn to 90 years. Lesions are generally located on head and face, and only a few of them were found on leg, shoulder, or neck, suggesting that sun exposure might be an important trigger factor. Disease duration varied from 3 months to 40 years; most of the patients had only one nodule, and 1 patient had four nodules (congenital CL).⁶ One patient synchronously had CL on the right cheek and syringoid eccrine carcinoma on the scalp.⁷ Most of the patients had surgery excision without recurrence, four patients received MMS,^8,9 one patient had shave excision and reoccurred,¹⁰ one patient metastasized in regional lymph nodes.⁵ Two patients had congenital CL,^6,11 (see Table 1).

Table 1 Clinical Findings in 96 Cases of CL

Reference	Number of Cases	Sex	Age at Diagnosis	Location	Duration	Evolution
Santa Cruz et al (1987, 1991),^Citation1,Citation2	13	8M/5F	21–55 (mean 39)	Face & scalp 10 Leg 2	Several months	Excision No recurrences
Civatte et al (1990)^Citation12	3	1M/2F	30–40 (mean 34)	Face 3	20 yeas	Excision No recurrences
Tsang et al (1991)^Citation13	1	1F	30	Eyelid	3–4 years	Excision No recurrences
Havard et al (1991)^Citation14	1	1F	75	Nose	–	Excision No recurrence
Wechsler et al (1992)^Citation15	1	1M	72	Face	–	Excision No recurrence
Masouye (1992)^Citation16	2	1M/1F	39/55	Preauricular Forehead	Several years	Excision No recurrences
Smith et al (1992)^Citation17	1	1F	36	Upper lip	–	Excision No recurrences
Requena et al (1992)^Citation18	2	2M	72/32	Forhead Cheek	1 year	Excsion –
Botella et al (1993)^Citation19	1	1M	36	Forehead	2 year	Excision No recurrences
Aloi et al (1993)^Citation20	2	1M/1F	48/52	Cheek/Temporal region	20/5 years	Excision No recurrences
Pardal et al (1994)^Citation21	1	1M	59	Upper lip	–	Excision –
Krahl et al (1996)^Citation22	2	2M	37/75	Eyebrow Nose	6/3 years	Excision No recurrences
Diaz et al (1996)^Citation23	3	3M	57/63/70 (mean 63)	Cheek/face 2 leg 1	8–30 years	Excision No recurrences
Poiares et al (1996)^Citation24	1	–	31	–	–	– –
Dahill et al (1998)^Citation7	1	1F	57	Cheek	–	Excision No recurrences
RodriguezDiaz et al (1998)^Citation25	1	1F	18	Cheek	Several years	Excision No recurrences
Yoon et al (1998)^Citation26	1	–	–	–	–	– –
McNiff et al (1999)^Citation27	5	3M/2F	32–62	Cheek 3 Preauricular 1 Forehead 1	6 months-40 years	Excision No recurrences
Pujol et al (1999)^Citation28	1	1F	34	Frontal area	3 years	Excision –
Inalöz et al (2001)^Citation29	2	2M	14/64	Thigh Forehead	4/1 years	Excision No recurrences
Yonghe Lin (2001)^Citation30	1	1M	49	Cheek	–	Excision –
Alsadhan et al (2003)^Citation31	1	1F	29	Preauricular	3 years	Excision –
Jaiswal et al (2003)^Citation32	1	1M	65	Temple	2 years	Excision No recurrences
Son et al (2004)^Citation33	1	1F	56	Cheek	2 years	Excision –
Persichetti et al (2005)^Citation34	1	1M	52	Cheek	3 years	Excision No recurrences
Reck et al (2007)^Citation11	1	1F	Newborn	–	–	Excision No recurrences
Lee et al (2007)^Citation35	1	1M	44	Preauricular	–	Excision –
Yoonseok et al (2007)^Citation36	1	1F	46	Postauricular	–	Excision No recurrences
Murphy et al (2007)^Citation37	1	1F	14	Eyebrow	1 year	Excision –
Kim et al (2008)^Citation38	1	1M	18	Temporal	10 years	Excision No recurrences
Chen et al (2009)^Citation39	2	1M/1F	9/32	Cheek Forhead	3 months/1 year	Excision No recurrences
Cheong et al (2009)^Citation40	2	–	–	Head Neck	–	– –
Verdolini et al (2010)^Citation41	1	1F	53	Eyelid	9 months	Excision No recurrences
Lopiccolo et al (2011)^Citation8	1	1M	Middle age	Cheek	–	MMS –
Kazakov et al (2011)^Citation5	1	1F	57	Upper lip	–	Excision & radiotherapy and cis-platin and radiochemoprotection by ethyol No recurrence, no metastasis
Hanlon et al (2012)^Citation7	3	1M/2F	25/40/87	Temple/Cheek Glabella	–	MMS No recurrence
Jiang et al (2012)^Citation42	1	1M	20	Cheek	7 years	Excision –
Fujimura et al (2012)^Citation43	1	1M	70	Cheek	40 years	Excision –
Maruthappu et al (2012)^Citation44	1	1F	30	Forhead	7 years	Excision No recurrence
Allen et al (2013)^Citation45	1	1M	60	Back	10 years	Excision No recurrence
Rao et a (2013)l^Citation46	1	1F	42	Face	1 year	Excision –
Ryan et al (2014)^Citation47	1	1F	67	Ear	Unknown	Excision No recurrence
Goyal et al (2016)^Citation48	9	5M/4F	23–90 (52)	Face & ear 6 Back 2 Shoulder 1	61–60 months (15 months)	Excision –
Pitarch et al (2016)^Citation49	1	1F	22	Retroauricular	Some months	Excision –
Fernandez et al (2017)^Citation6	1	1F	8	Forehead (4 nodules)	8 years (from newborn)	Excision –
Keesecker et al (2017)^Citation50	1	1F	44	Eyebrow	9 months	Excision –
Tang et al (2020)^Citation51	1	1F	50	Nose	1 year	Excision –
Rajabi et al (2021)^Citation8	1	1F	21/18	Forehead	6 months (4 years)	Excision Shave excision Recurrence
Monteagudo et al (2021)^Citation3	11	4M/7F	30–78	Face 10 Thigh 1	–	– –

Typically, CL featured as slow growing, asymptomatic, skin-color or pink nodules, dome-shaped, usually on the head, particularly the cheek, eyebrow, and forehead, small sized (usually less than 1 cm in diameter). One reported case applied dermoscopic examination. It showed prominent telangiectatic vessels traversing the lesion and branching into finer capillaries. Three peripheral areas were appreciated, divided by the arborizing telangiectasis, with dotted vessels and some glomerular vessels on a white-to-pink background.⁴⁹ Triphasic tumor with epithelial islands, lymphocytic infiltrates and desmoplastic stroma, unremarkable epidermis were the main histopathologic features of CL. A well-circumscribed tumor located on the dermis, consisting of lobules unconnected or occasionally connected in some areas to the epidermis. The lobules were constituted by a rim of basaloid cells and peripheral palisading, and a central area contained numerous inflammatory cells including lymphocytes (CD3+ T cells) and histiocytes (numerous Langerhans’ cells and the characteristic large RS-L cells with amphophilic cytoplasm, vesicular nuclei, and prominent nucleoli). No peritumoral cleft was visible. No mitoses or nuclear atypia was observed. Rudimentary follicular papillae/hair germs may be present focally. A dense and fibrotic stroma was surrounded the lobules. We also summarized the reported immunohistochemistry staining of CL (see Table 2).

Table 2 Cell Types and Positive Immunostaining

Cell Type	Positive Antibodies
Epithelial cells	AE1/AE3+, BerEP4+, Bcl-2+, EMA+, CK15+, PHLDA1+, AR+, CK17+, CK20+
Lymphocyte	CD45+
T cells	CD3+, CD4+, FoxP3+
B cells	CD20+
Langerhans cells	CD68+, CD1a+, S100+
The stroma	CD34 +
RS-L cells	Jagged-1+, Notch1+, NKX3.1 +, CD30+

CL should be differentiated with several skin diseases presenting asymptomatic, chronically growth nodules in the head and neck area. Basal cell carcinoma (BCC) shows histological features not seen in CL, such as mitotic and apoptotic bodies, clefting artifact with stroma mucin in the retraction space. Furthermore, immunohistochemical study showed scattered Merkel cells (CK20+) in CL but absent in BCC. CK17, while a patchy and peripheral rim staining in the basaloid islands of CL, diffuse positive staining in BCC.⁴⁸ Another useful marker, AR, which usually showed focal immunoreactivity in BCC, was diffuses strong immunostaining in CL.³ Trichoblastoma, many reports considered CL similar to trichoblastoma, CL was classified as an adamantoid variant of trichoblastoma in the latest WHO classification.⁵² However, there are differences in many aspects: firstly, there are intraepithelial lymphocytes and RS-L cells in CL, but not in trichoblastoma; secondly, the latest research found that although both CL and trichoblastoma were positive for CK15, CL was also positive for AR while the latter was AR negative.³ Trichoepithelioma, trichoepithelioma is a benign adnexal tumor of follicular germinative derivation. Although could be single, most are multiple and seen in patients with multiple familial trichoepithelioma or Brooke–Spiegler syndrome. They usually begin during puberty, often appear clinically and histologically similar to BCC.⁵³ Furthermore, trichoepithelioma is AR negative.⁵⁴ Lymphoepithelioma-like carcinoma of the skin(LELCS), LELCS normally affects elderly patients and most often found in the sun-exposed areas of the head. Histologically, LELCS is an epithelial neoplasm located mainly in the deep dermis and hypodermis, with atypical epithelial cells and mitotic figures, it is now classified as a variant of squamous cell carcinoma, and can be found in many organs besides the skin.⁵⁵ Other diseases such as clear cell syringoma, dermal thymus, pseudolymphoma, congenital subcutaneous dendritic cell-rich lymphoepithelial hamartoma should also be differentiated.

As for the histogenesis, at the beginning, CL was suggested as adnexal origin since it had immature pilosebaceous differentiation. Later, some authors suggested it represented a form of BCC with pilar or eccrine differentiation and pilosebaceous neoplasm as it closely related to trichoepithelioma. In some cases, there were foci of ductal differentiation, with luminal positivity for CEA and EMA, and postulate that some CL represent a form of immature sweat gland tumor with ductal differentiation.¹⁹ Now it is classified as an adamantoid variant of trichoblastoma in the latest WHO classification.¹⁴ Recent studies showed that CL being a benign tumor with AR and hair follicle bulge stem cell marker (CK15) expression, RS-L cell-derived Notch 1 ligand, and common EGFR gene mutations.³ It is now considered different with trichoblastoma. Furthermore, EGFR hotspot missense mutations in CL were considered pathogenic, and it was hypothesized that EGFR mutations may provoke a continuous hair follicle stem cell proliferation, and together with the Notch pathway stimulation, responsible for CL tumor growth.^3,56

Complete excision is currently the first treatment choice for CL. Recurrence and metastasis were rarely reported. To our knowledge, only one patient reoccurred after shave excision and one patient revealed metastatic involvement of submandibular lymph nodes. The reemergence of the lesion might be attributed to the insufficient margin of shave excision. The case of CL arising in association with a LELCS suggests that CL may rarely progress to a malignant neoplasm capable of metastatic spread. Mohs surgery was applied by four patients, considering the time-consuming and relatively expensiveness, Mohs surgery was particularly used in cases that the tumor margins were not clinically well defined or the tumor located in anatomically sensitive areas where tissue preservation is critical.

Conclusion

CL is a rare skin tumor, presented as slow growing and benign biological behavior. In clinic, it is easily misdiagnosed as BCC, pilomatricoma, skin cyst, etc. Complete surgical excision and histopathological examination are the main treatment and diagnosis methods at present. Histopathologically, it needs to be differentiated from BCC, trichoblastoma, trichoepithelioma, clear cell syringoma, dermal thymus, LELCS, etc. The pathogenesis is still unclear, mainly because the extremely low incidence, so it is difficult to obtain enough specimens for in-depth clinical and laboratory research. Since incomplete resection may cause recurrence, few patients even have the risk of malignancy and metastasis to regional lymph nodes. Physical therapy options such as freezing, laser and simple shaving should be avoided, but there is no need to overtreat either.

Disclosure

The authors report no conflicts of interest in this work.

Acknowledgments

Publication of the case details was approved by Beijing Chaoyang Hospital, Capital Medical University.